COMMUNIQUÉS West-GlobeNewswire

-
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
25/07/2025 -
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
25/07/2025 -
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
25/07/2025 -
La Commission européenne approuve DARZALEX® (daratumumab) comme premier traitement autorisé pour les patients présentant un myélome multiple indolent à haut risque
25/07/2025 -
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
25/07/2025 -
Cronos Group Inc. to Hold 2025 Second Quarter Earnings Conference Call on August 7, 2025
25/07/2025 -
Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast
25/07/2025 -
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
25/07/2025 -
Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds
25/07/2025 -
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
25/07/2025 -
Nelipak® Breaks Ground on New Healthcare Packaging Facility in Grecia, Alajuela Costa Rica
25/07/2025 -
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
25/07/2025 -
Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
25/07/2025 -
RadNet, Inc. Announces Date of its Second Quarter 2025 Financial Results Conference Call
25/07/2025 -
Communiqué de presse : Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
25/07/2025 -
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
25/07/2025 -
Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection
25/07/2025 -
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
25/07/2025 -
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
25/07/2025
Pages